Susanne Crowe

870 total citations
22 papers, 695 citations indexed

About

Susanne Crowe is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Susanne Crowe has authored 22 papers receiving a total of 695 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Surgery and 7 papers in Molecular Biology. Recurrent topics in Susanne Crowe's work include Diabetes Treatment and Management (11 papers), Pancreatic function and diabetes (8 papers) and Metabolism, Diabetes, and Cancer (7 papers). Susanne Crowe is often cited by papers focused on Diabetes Treatment and Management (11 papers), Pancreatic function and diabetes (8 papers) and Metabolism, Diabetes, and Cancer (7 papers). Susanne Crowe collaborates with scholars based in United States, Germany and Switzerland. Susanne Crowe's co-authors include Thomas Hach, Ele Ferrannini, Kevin D. Hall, Giulia Ferrannini, Arjun Sanghvi, Odd Erik Johansen, Hans J. Woerle, Ian J. Neeland, Uli C. Broedl and Darren K. McGuire and has published in prestigious journals such as The Lancet, Circulation and Blood.

In The Last Decade

Susanne Crowe

21 papers receiving 673 citations

Peers

Countries citing papers authored by Susanne Crowe

Since Specialization

Citations

This map shows the geographic impact of Susanne Crowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susanne Crowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susanne Crowe more than expected).

Fields of papers citing papers by Susanne Crowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susanne Crowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susanne Crowe. The network helps show where Susanne Crowe may publish in the future.

Co-authorship network of co-authors of Susanne Crowe

This figure shows the co-authorship network connecting the top 25 collaborators of Susanne Crowe. A scholar is included among the top collaborators of Susanne Crowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susanne Crowe. Susanne Crowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Longitudinal Evaluation of Bone Safety in Children and Adolescents With HIV-1 Starting Tenofovir Alafenamide-Containing Antiretroviral Therapy 2025 ·Journal of the Pediatric Infectious Diseases Society ·(unknown), Aditya H. Gaur, Jaime G. Deville, Pope Kosalaraksa, Renate Strehlau, Elizabeth Castaño, Afaaf Liberty, Susanne Crowe, (unknown), Vinícius Vieira, Kathryn Kersey, Natella Rakhmanina, Catherine M. Gordon	0
2	Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study 2022 ·Dermatology and Therapy ·Peter Foley, Tsen‐Fang Tsai, Karl Rodins, (unknown), Alfred Ammoury, (unknown), (unknown), Susanne Crowe, (unknown), Effie Pournara, (unknown), Yu‐Huei Huang	13
3	Two-year long safety and efficacy of deferasirox film-coated tablets in patients with thalassemia or lower/intermediate risk MDS: phase 3 results from a subset of patients previously treated with deferasirox in the ECLIPSE study 2020 ·Experimental Hematology and Oncology ·Immacolata Tartaglione, Raffaella Origa, Antonis Kattamis, Michael Pfeilstöcker, (unknown), Susanne Crowe, (unknown), Bruno Vincenzi, (unknown)	9
4	Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H1-Antihistamines in Asia, Middle-East and Africa: Results from the AWARE-AMAC study 2020 ·World Allergy Organization Journal ·Chia‐Yu Chu, (unknown), Nancy Agmon‐Levin, Nilgün Atakan, (unknown), (unknown), (unknown), Kanokvalai Kulthanan, (unknown), Fares Zaitoun, Susanne Crowe, (unknown), (unknown), Elise Dekker	9
5	Efficacy and safety of linagliptin in type 2 diabetes patients with self-reported hepatic disorders: A retrospective pooled analysis of 17 randomized, double-blind, placebo-controlled clinical trials 2016 ·Journal of Diabetes and its Complications ·Nobuya Inagaki, Wayne Huey‐Herng Sheu, David R. Owens, Susanne Crowe, Amit Bhandari, Yan Gong, Sanjay Patel	5
6	Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials 2016 ·Diabetes Obesity and Metabolism ·Kun‐Ho Yoon, Rimei Nishimura, Jisoo Lee, Susanne Crowe, Afshin Salsali, Thomas Hach, Hans J. Woerle	18
7	Empagliflozin in combination with oral agents in young and overweight/obese Type 2 diabetes mellitus patients: A pooled analysis of three randomized trials 2016 ·Journal of Diabetes and its Complications ·Irene Romera, Ramón Gomis, Susanne Crowe, Pedro de Pablos‐Velasco, (unknown), Arantxa García, (unknown), Ebrahim Naderali	7
8	Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus 2015 ·Diabetes and Vascular Disease Research ·Ian J. Neeland, Darren K. McGuire, Robert Ćhilton, Susanne Crowe, Søren S. Lund, Hans J. Woerle, Uli C. Broedl, Odd Erik Johansen	141
9	Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition 2015 ·Diabetes Care ·Giulia Ferrannini, Thomas Hach, Susanne Crowe, Arjun Sanghvi, Kevin D. Hall, Ele Ferrannini	279
10	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials 2015 ·Postgraduate Medicine ·James Thrasher, David S. Kountz, Susanne Crowe, Hans‐Juergen Woerle, Maximilian von Eynatten	3
11	Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies 2014 ·Clinical Therapeutics ·Michael Lehrke, Nikolaus Marx, Sanjay Patel, Thomas Seck, Susanne Crowe, Karen Cheng, Maximilian von Eynatten, Odd Erik Johansen	51
12	Abstract 16518: The Sodium Glucose Co-Transporter 2 Inhibitor (SGLT2i) Empagliflozin Reduces Weight and Markers of Visceral Adiposity (VA) in Type 2 Diabetes (T2D) in Short- and Intermediate Term 2014 ·Ian J. Neeland, Darren K. McGuire, Robert Ćhilton, Susanne Crowe, Søren S. Lund, Hans‐Juergen Woerle, Uli C. Broedl, Odd Erik Johansen	3
13	Abstract 16709: Contrasting Influences of Renal Function on Blood Pressure and HbA1c Reductions With Empagliflozin in Patients With Type 2 Diabetes and Hypertension 2014 ·Circulation ·David Z.I. Cherney, Mark E. Cooper, Ilkka Tikkanen, Susanne Crowe, Odd Erik Johansen, Søren S. Lund, Hans J. Woerle, Uli C. Broedl, Thomas Hach	1
14	Expression of inhibitory Fc receptor (FcγRIIB) is a marker of poor response to rituximab monotherapy in follicular lymphoma 2013 ·The Lancet ·(unknown), Margaret Ashton‐Key, Sergio Cogliatti, Susanne Crowe, Mark S. Cragg, (unknown), Michele Ghielmini, Peter Johnson	4
15	EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer 2013 ·PLoS ONE ·Florent Baty, Sacha I. Rothschild, Martin Früh, Daniel Betticher, (unknown), Richard Cathomas, Daniel Rauch, Oliver Gautschi, Lukas Bubendorf, Susanne Crowe, Francesco Zappa, Miklos Pless, Martin Brutsche	9
16	VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528 2012 ·Lung Cancer ·Oliver Gautschi, Anne‐Marie C. Dingemans, Susanne Crowe, Solange Peters, Heinrich Röder, Julia Grigorieva, Joanna Roder, Francesco Zappa, Miklos Pless, Martin Brutsche, Florent Baty, Lukas Bubendorf, Shu‐Fang Hsu Schmitz, (unknown), David P. Carbone, Rolf A. Stahel, Egbert F. Smit	25
17	Clinically significant bleeding in incurable cancer patients: effectiveness of hemostatic radiotherapy 2012 ·Radiation Oncology ·Nikola Čihorić, Susanne Crowe, Steffen Eychmüller, Daniel M. Aebersold, Pirus Ghadjar	43
18	Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma 2012 ·Radiation Oncology ·(unknown), Beat Bojaxhiu, Susanne Crowe, A. Arnold, Peter Manser, Wock Hallermann, Daniel M. Aebersold, Pirus Ghadjar	29
19	Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05) 2012 ·Lung Cancer ·Francesco Zappa, (unknown), Daniel Betticher, Roger von Moos, Lukas Bubendorf, Adrian F. Ochsenbein, Oliver Gautschi, Elisabeth Oppliger Leibundgut, Patrizia Froesch, Rolf A. Stahel, Thomas Heß, Daniel Rauch, (unknown), Michael Mayer, Susanne Crowe, Peter Brauchli, Karin Ribi, Miklos Pless	27
20	SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity. 2012 ·Blood ·Christoph Driessen, Dagmar Hess, Thomas Pabst, Sarah R. Haile, Markus Joerger, Roger von Moos, Catherine Berset, Susanne Crowe, Hilde Rosing, Herman S. Overkleeft, C. Sessa, Marianne Kraus	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact